


Amendments to the Claims:

1. (Currently amended) An antisense compound having an uncharged morpholino backbone and a base sequence between 12 and 25 nucleotide bases in length which is complementary to a target region of a selected preprocessed mRNA coding for a human p53 protein selected from the group consisting of myc, myb, rel, fos, jun, abl, bcl, p53, an integrin, a cathedrin, a telomerase, a cytokine, a kinase, a receptor protein, hCG, HIV rev, human papilloma virus, and human parvovirus B19,

where the 5' end of the target region is 1-25 bases downstream of a normal splice acceptor site in said preprocessed mRNA.

2. (Currently amended) The compound of claim 1, having intersubunit linkages selected from the group consisting of the structures presented in Figs. 2AA-2EE wherein said backbone comprises morpholino subunits, as shown below, where P_i is a purine or pyrimidine base-pairing moiety effective to bind to a base in a polynucleotide, and uncharged phosphorus-containing linkages, one to three atoms long, joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit.



3. (Currently amended) The compound of claim 2, wherein the linkage is a phosphorodiamidate linkage as represented at Figure 2B-B by -P(=Z)(X)-Y-, where X=NH₂, NHR, or NRR', Y=O, and Z=O, or where X=OR, Y=NH or NR', and Z=O, and R and R' are groups which do not interfere with target binding.

4. The compound of claim 3, wherein R and R' are moieties independently selected from alkyl, polyalkyleneoxy, and a combination thereof, which may be substituted with one or more groups selected from hydroxy, alkoxy, amino, alkylamino, thiol, alkanethiol, halogen, oxo,

carboxylic acid, carboxylic ester, and inorganic ester.

5. The compound of claim 4, wherein each said moiety R and R', independent of substitution, is from 1 to 6 atoms long.

6. The compound of claim 3, wherein NRR' represents a nitrogen heterocycle having 5-7 ring atoms selected from nitrogen, carbon, oxygen, and sulfur, and having at least as many carbon ring atoms as non-carbon ring atoms.

7. The compound of claim 6, wherein the 5' end of the target region is 10-15 bases downstream of a normal splice acceptor site.

8-17. (Withdrawn)

18. (Currently amended) The compound of claim 17 1, wherein the base sequence is SEQ ID NO: 35.

19-22. (Withdrawn)

23-33. (Cancelled)

34-37. (Withdrawn)

38. (Cancelled)